Table 1.

Ongoing trials testing immunotherapy (IT) in combination with radiation therapy (RT) in patients with NSCLC or HNSCC.

NCT number	Study phase	Disease stage	Trial design (Experimental arm)	Estimated primary completion date
NCT03391869	Phase 3	Metastatic NSCLC	Local Consolidation Therapy (RT or surgery) after Nivolumab and Ipilimumab (LONESTAR)	December, 2022
NCT03523702	Phase 2	Locally Advanced NSCLC	Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial (SPRINT)	August, 2020
NCT03176173	Phase 2	Metastatic NSCLC	Radical-Dose Image Guided Radiation Therapy in Treating Patients with Metastatic NSCLC undergoing IT	June, 2020
NCT03110978	Phase 2	Stage I, selected IIa or isolated recurrent NSCLC	Immunotherapy Plus Stereotactic Ablative Radiotherapy (I-SABR) vs. SABR Alone	June, 2022
NCT03164772	Phase 2	Metastatic NSCLC	Safety and preliminary efficacy of the addition of a vaccine therapy to 1 or 2 checkpoint inhibitors for NSCLC.	March, 2021
NCT03313804	Phase 2	HNSCC and NSCLC undergoing IT	Short-course radiation to a single systemic (non-CNS) site within 14 days of the beginning of IT	June, 2018
NCT02999087	Phase 3	Locally advanced HNSCC front-line	Avelumab and Cetuximab plus RT vs Cetuximab-RT and Cisplatin-RT	October, 2019
NCT03085719	Phase 2	Advanced HNSCC after first line therapy	Immunotherapy (Pembrolizumab) in combination with high dose and low dose radiation therapy	October, 2020
NCT03317327	Phase 1/2	Recurrent HNSCC	Re-irradiation and Nivolumab in loco-regionally recurrent HNSCC	November, 2023
NCT03247309	Phase 1	Recurrent HNSCC and NSCLC	TCR-engineered T Cells in Solid Tumors With Emphasis on NSCLC and HNSCC (ACT engine)	December, 2019
NCT02892201	Phase 2	HNSCC with residual disease	Pembrolizumab after RT in patients with residual disease (biopsy proven)	December, 2018
NCT03247712	Phase 1/2	HNSCC before surgery	Test the safety of neoadjuvant immune-radiotherapy to down-staging HNSCC prior to surgical resection.	December, 2025